Recent years, studies have demonstrated that hyperglycemia is one of the main manifestations after cardiac surgeries, which contributes to myocardial injuries and increases the chance of subsequent complications and mortality in such patients.
| INTRODUC TI ON
Acute glucose metabolic disorders are commonly present in critical illness, especially following trauma, 1 sepsis, 2 burns, 3 myocardial infarction, 4 and surgery, 5 but the role of perioperative glucose metabolism disorders remains controversial. It has been suggested that mild hyperglycemia ensures glucose supply to important organs such as the heart, brain, and kidney to meet the need of increased metabolism in acute illness. 6 However, recent clinical data have suggested that severe postoperative hyperglycemia greatly impedes the energy substrates supply for crucial organs, which is closely associated with increased mortality in critically illness patients. 7, 8 Cardiopulmonary bypass (CPB)-induced cardiac injury is one of the most serious forms of critical illness, which is characterized by stress, hyperglycemia, inflammation, hyperactive metabolic responsiveness, 9, 10 and glucose metabolism disorders. 11 It has been
shown that impaired myocardial glucose uptake results in myocardial damage and cardiac dysfunction in myocardial ischemia/ reperfusion injury or in diabetes. 7, 12 Moreover, acute myocardial insulin resistance has been shown to play an important role in cardiac dysfunction and increases the complications and mortality in an animal model of severe burn injury. 13 However, strategies aimed to attenuate the extent of myocardial injuries induced by glucose metabolic disorder following cardiac surgery are inadequately studied.
Previous study revealed that glucose transporters (GLUTs), such as GLUT4, GLUT1, and GLUT8, were found to exist in the normal heart, 14 and decreased plasma membrane content of GLUT4 contributes to acute myocardial glucose metabolic disorder induced by CPB. 11 In addition, Adenosine 5'-monophosphate-activated protein kinase (AMPK), a key sensor of cellular energy status, plays a major role in the adaptive response to stress by modulating myocardial glucose metabolism. 15 The critical importance of AMPK function in the heart was highlighted by the observation that genetic mutations in the PRKAG2 gene, which encode the γ-2 regulatory subunit of AMPK, gives rise to a novel cardiac glycogenosis syndrome in humans. 16, 17 Moreover, myocardial glucose uptake during ischemia was reported to be affected by impaired AMPK 2-catalytic subunits in the heart. [18] [19] [20] [21] On the contrary, activation of AMPK showed beneficial effect against multiple myocardial injury models by modulating myocardial glucose metabolism. [22] [23] [24] [25] Therefore, a rat model of CPB was applied in this study to investigate the role of AMPK in modulating myocardial glucose metabolism and thus the overall cardioprotective effect.
| MATERIAL S AND ME THODS

| Cardiopulmonary bypass protocol
The experiments were performed in adherence with the National
Institutes of Health Guidelines for the Use of Laboratory Animals
and were approved by the Fourth Military Medical University
Committee on Animal Care. Male Sprague-Dawley rats (14 weeks old, 450-550 g) were used for the experiments (n = 6 in each group). The rat cardiopulmonary bypass model was developed according to previously described approaches with some modifications. 26, 27 Briefly, rats were anesthetized with pentobarbital (60 mg/kg, intraperitoneal administration) at the beginning, and additional pentobarbital was used to maintain anesthesia. The right femoral artery was cannulated for arterial pressure monitoring and blood sample collection (using a 24G catheter). After administration of heparin (250 U/kg), a 16G catheter, which was modified to a multi-sided orifice cannula in the forepart, was inserted into the right jugular vein and advanced to the right atrium.
This approach was used as a vein drain-line in CPB. A 22G catheter for arterial infusion was introduced into the contralateral tail artery.
The mini-cardiopulmonary bypass circuit comprised a venous reservoir (10 mL), a specially designed membrane oxygenator, and a roller pump (BT00-300M, Lange Co, Shanghai, China). All components were connected with polyethylene tubes. Body central temperature was monitored with a rectal probe and kept at 36.5-38.3°C
by a heat lamp that was placed around the animal and the CPB equipment. The circuit was primed with 10 mL of a solution comprising heparin (1 mL, 250 U/kg), synthetic colloid (8 mL), and sodium bicarbonate (1 mL). At the initiation of perfusion, the flow rate was gradually increased to 100 mL/kg/min and maintained for 120 minutes, and then it was turned down step-by-step to maintain hemodynamic stability. Before the rat was weaned from CPB, the tail artery catheter was removed, and the right jugular vein catheter was drawn back to the superior vena cava. The remaining priming solution was infused gradually when the main arterial pressure was <60 mm Hg.
After 1 hour of intensive postoperative care, catheters to the right jugular vein and the femoral artery were de-cannulated. Next, the neck, the tail, and groin incisions were sutured. Throughout the experiment, the mean arterial pressure was maintained at approximately 60-80 mm Hg. Before the start of CPB, the experimental rats randomly received one of the following treatments: the sham group (only cannulated but not undergoing CPB); the CPB group (cannulated for CPB and undergoing CPB for 2 hours); and 3) the AICAR group (loading dose of AICAR at 2.5 mg/kg/min infused for 5 minutes before CPB and maintained at 0.5 mg/kg/min).
| Measurements of cardiac injury markers
Plasma cardiac troponin I and creatine kinase MB levels were measured by commercially available high-sensitivity ELISA kits (Wuhao Company, Shanghai, China) according to the manufacture's instructions.
| Echocardiography measurements
Echocardiography was performed using an ACUSONS sequoia 512 ultrasound machine (Siemens, Erlangen, Germany) before CPB and 2 hours post-CPB. A 14-MHz probe was used to obtain M-mode imaging, and two-dimensional images from the parasternal long-axis view at the apical four-chamber view and at the level of the papillary 
| In vivo measurement of cardiac glucose uptake using PET
To visualize cardiac glucose uptake, rats were injected with an average of 1 µCi 18F-FDG were allowed to rest for 60 minutes to allow glucose uptake. After that, animals were anesthetized by isoflurane, and PET/CT images were acquired using a nano-scan PET/CT scanner (Mediso, Budapest, Hungary).
| Overexpression of AS160-4P by adenovirus infection
Adenoviral vectors encoding human AS160-4P were provided by Gene Chem, Shanghai, China. The AS160-4P was mutated at four PAS motifs (ie, Ser318, Ser588, Thr642, and Ser751), rendering these sites incapable of being phosphorylated (4P). In brief, the cDNA for . Data were shown as the mean ± SEM from 3 to 6 independent experiments. *P < 0.05 vs both the groups before CPB, # P < 0.05 vs the sham group 2 h post-CPB circulate to the coronary arteries and perfuse the heart without direct manipulation of the coronary arteries. Subsequently, the clamp on the pulmonary and aortic artery was released. Cardiopulmonary bypass was performed 1 week after gene transfer.
| AMPK activity assay
Adenosine 5'-monophosphate-activated protein kinase activity was assessed as previously described. 29, 30 Briefly, AMPK was immunoprecipitated from 500 μg of the protein that was obtained from cardiac tissue by incubation at 4°C overnight on a roller mixer using AMPK specific antibodies (1:80) and protein A/G-agarose beads (1:10; Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA).
Following several washes, the activity was measured in the pres- Label incorporation into the SAMS peptide was quantified using a LabLogic (Brandon, FL) scintillation counter.
| Extraction of whole tissue and plasma membrane fractionation
Hearts samples (n = 6 per group) were rapidly harvested, and the whole protein samples were prepared by homogenizing myocardial tissues in ice-cold lysis buffer. The lysates were centrifuged and the supernatants were retained. Heart plasma membrane fractions were prepared as described previously. 30 Ventricle tissue 
| Western blotting
Western blotting was performed as previously described.
9
Antibodies targeting against AMPK (1:1000 dilution, #5832), phosphorylated AMPK (1:1000 dilution, #8208), AS160 (1:1000 dilution, #2670), GLUT1 (1:1000 dilution, #12939), GLUT4 (1:1000 dilution, #2213), Gβ (1:1000 dilution, #3274), and GAPDH (1:1000 dilution, #5174) were all purchased from Cell Signaling Technology, Beverly, MA, USA. Antibodies against phosphorylated AS160 (1:1000 dilution, #700565) were purchased from BIOSOURCE International, F I G U R E 2 Impaired myocardial glucose uptake and reduced plasma membrane GLUT4 following CPB. The following assays were detected at preoperation and at 2 h post-CPB in sham and CPB groups. A, Representative images of myocardial 18F-fluoro-deoxy-d-glucose (18F-FDG) uptake with positron emission tomography (PET). B, Quantification of maximum standardized glucose uptake values (SUVmax). C, Representative Western blots of myocardial membrane and total GLUT1 and GLUT4, GAPDH and Gβ were used as internal loading controls. D, Quantification of myocardial membrane GLUT1 and GLUT4. E, Representative immunofluorescence staining of GLUT4 in the heart samples. Data were represented as the mean ± SEM from 3 to 6 independent experiments. *P < 0.05 vs both the groups at pre-CPB, # P < 0.05 vs the sham group at 2 h post-CPB [Colour figure can be viewed at wileyonlinelibrary.com] Camarillo, CA, USA. The phosphorylated AMPK or phosphorylated AS160 blots were stripped in a dedicated stripping buffer at 50°C for 30 minutes and reblotted for total AMPK or AS160. GAPDH and Gβ were used as an internal control for loading variability for the total or membrane protein input, respectively. Blots were imaged and relative protein levels were determined using the Odyssey Infrared Imaging System Version (LI-COR, Inc., Lincoln, NE, USA).
| ATP content assay
For ATP determinations, biopsy samples were homogenized and deproteinized in 5% trichloroacetic acid. Samples were adjusted to pH 7.4 in Tris-acetate buffer and immediately analyzed with a bioluminescence assay using recombinant firefly luciferase (Invitrogen, Carlsbad, CA).
| Statistical analysis
Values are described as mean ± SEM. 
| RE SULTS
| CPB resulted in cardiac injury, decreased myocardial ATP content, and impaired cardiac function
Severe cardiac injury and cardiac dysfunction are the main consequences of CPB surgery. [31] [32] [33] [34] [35] Consistent with these findings, our data showed that the levels of cardiac injury biomarkers, including plasma creatine kinase MB and troponin I, significantly elevated 2 hours after CPB ( Figure 1A,B) . Meanwhile, myocardial ATP content markedly decreased in CPB group compared with those in sham group ( Figure 1C) . Moreover, CPB notably blunted cardiac function as evidenced by decreased cardiac left ventricular ejection fraction (LVEF) and more dilated left ventricular chamber at diastolic period (LVESD) (Figure 1D-F) .
| Impaired myocardial glucose uptake and reduced plasma membrane GLUT4 following CPB
Previously studies have shown that impaired myocardial glucose uptake involved in myocardial injury and cardiac dysfunction. To further assess the myocardial glucose metabolism in the heart after CPB, myocardial glucose uptake was assessed by 18F-fluoro-deoxy- Figure 2A ,B, myocardial glucose uptake was significantly blunted 2 hours after CPB as compared with that in the sham group. Western blot further revealed that CPB resulted in a sharp reduction of membrane content of GLUT4 but not the total amount of GLUT4, while the total and membrane GLUT1 kept unchanged in all groups ( Figure 2C,D) . This was further proved by immunofluorescence findings in the heart samples, illustrating that CPB significantly decreased the translocation of GLUT4 to the plasma membrane ( Figure 2E ).
| AMPK activation improved CPB-induced cardiac dysfunction by restoration of myocardial glucose uptake and attenuation of cardiac injury
Considering AMPK is an important energy regulator under stressful conditions which has been shown to effectively protecting heart from multiple cardiac injuries, we further explored the role of AMPK in CPB induce cardiac injury. As the glucose uptake assay illustrated in Figure 3A Meanwhile, improved LVEF and less dilated LVESD were also observed in the AICAR-CPB group ( Figure 3G-H) . These data suggested that preactivation of AMPK-alleviated myocardial glucose uptake impairment, at least in part, protected heart from CPB-induced injury, and thus improved post-CPB cardiac function.
| Preactivation of AMPK-alleviated acute myocardial glucose uptake impairment via metabolism disorders-AS160-GLUT-4 signal pathway
The above experiments have illustrated that preactivation of AMPK by AICAR obviously protected heart from CPB-induced cardiac dysfunction and injury through improved myocardial glucose uptake; hence, the molecular mechanism was further explored. As illustrated in Figure 4A -C, CPB significantly blunted phosphorylation and activity of AMPK, which was markedly reversed by administration of AICAR before CPB. In parallel to this finding, phosphorylated AS160 was also significantly decreased after CPB operation, but preactivation of AMPK by AICAR partially recovered phosphorylated level of AS160 ( Figure 4A,D) . Moreover, reduced myocardial plasma membrane content of GLUT4 after CPB was notably up-regulated in the CPB+AICAR group, as evidenced by Western blotting and immunofluorescence results ( Figure 4A,E,F) .
F I G U R E 4
Preactivation of AMPK-alleviated myocardial glucose uptake impairment via AS160-GLUT-4 signal pathway. The following assays were detected at preoperation and at 2 h post-CPB, and AICAR or saline were infused 5 min before all the operations. A, Representative Western blots of myocardial phosphorylated and total AMPK and AS160, plasma membrane and total GLUT4, GAPDH and Gβ were used as internal loading controls. B, Quantification of myocardial phosphorylated and total AMPK. C, Quantification of myocardial AMPK activity. D, Quantification of myocardial phosphorylated and total AS 160. E, Quantification of myocardial membrane GLUT4. F, Representative immunofluorescence staining of GLUT4 in the heart samples. Data were represented as the mean ± SEM from 3-6 independent experiments. *P < 0.05 vs both the groups before CPB, # P < 0.05 vs the CPB group 2 h post-CPB [Colour figure can be viewed at wileyonlinelibrary.com]
| In vivo deliver of AS160-4P impaired AMPKstimulated myocardial plasma membrane GLUT4 distribution and glucose uptake
To further prove whether AS160 participated in AMPK-modulated membrane translocation of GLUT4, empty vector or the AS160-4P construct was transferred into the myocardium by adenovirus expression system. AS shown in Figure 5A , adipocytes. 36 These data suggested that phosphorylation of AS160 is required for AMPK-modulated myocardial glucose uptake in the setting of CPB.
| In vivo deliver of AS160-4P abolished AMPKmodulated cardioprotective effect
To further examine whether AS160 mediates AMPK-modulated cardioprotective effect, cardiac injury markers, myocardial ATP content, and cardiac function were measured in the CPB groups infected with empty vector or AS160-4P. As illustrated in Figure 6A ,B, blocking of AS160 led to markedly increased serum levels of creatine kinase MB and troponin I in CPB treated with AICAR group 2 hours post-CPB, while the level of cardiac ATP content decreased greatly in the AICAR+AS1604P group compared with that in the AICAR+empty vector group ( Figure 6C ).
F I G U R E 5
In vivo deliver of AS160-4P impaired AMPK-stimulated myocardial plasma membrane GLUT4 distribution and glucose uptake. Transfection of AS160-4P was performed 1 wk before the surgeries. The following assays were detected at preoperation and at 2 h post-CPB, and AICAR was infused 5 min before all the operations. A, Representative Western blots of myocardial AS160 and AS160-4P 1 wk postinfection. B, Quantification of myocardial AS160 and AS160-4P 1 wk postinfection. C, Representative Western blots of myocardial plasma membrane and total GLUT4, GAPDH, and Gβ were used as internal loading controls. D, Quantification of myocardial plasma membrane GLUT4. E, Representative images of myocardial 18F-fluoro-deoxy-d-glucose (18F-FDG) uptake with positron emission tomography (PET). F, Quantification of maximum standardized glucose uptake values (SUVmax). Data were shown as the mean ± SEM from 3-6 independent experiments. *P < 0.05 vs the empty PCAGGS group (in A), *P < 0.05 vs both the groups before CPB, # P < 0.05 vs the CPB treated with empty PCAGGS group 2 h after CPB (in C-F) [Colour figure can be viewed at wileyonlinelibrary.com]
Besides these data, AS1604P also notably eliminated the beneficial effect of AICAR on the heart function after CPB, as evidenced by reduced LVEF and more dilated left ventricular end-systolic dimensions (LVESD) (Figure 6D-F) . Thus, these data implied that interrupting the phosphorylation of AS160 abolished the cardioprotective effect of AMPK in CPB.
| D ISCUSS I ON
In this study, we found that preactivation of AMPK-alleviated myocardial glucose metabolic disorders at the early stage after CPB by modulating AS160-GLUT4 to increase myocardial glucose uptake, which ultimately contributed to attenuated cardiac injury and improved heart function.
The majority of researchers hold the view that insulin resistance is a pathological response of the physiological state of cellular, tissue, and organismal systems biology, in which glucose uptake and utilization is diminished. 37 The development of acute insulin resistance is complex and involves multiple factors and intracellular signaling pathways. 38 Various insults, including mechanical, trauma, hypotension, coagulation disturbances, hypothermia, and hemodilution, took place during the CPB procedure, which result in severely disturbed imbalance in the internal environment such as hyperglycemia, and hyperlactatemia. 39 Moreover, these insults also inevitably suppress the insulin signal transduction pathway, 40 and simultaneously increase plasma level of glucocorticoids that also indirectly exacerbates insulin resistance. 41, 42 Compared with insulin resistance that chronically develops in diabetics, the underlying mechanism of acute glucose metabolism disorders in acute injury and critical illness is poorly understood. 38 It was reported that increased proinflammatory cytokine, tumor necrosis factor alpha (TNF-α), induced by burn injury or trauma, led to insulin resistance and decreased glucose uptake in myocardial tissues. 43 GLUT4, GLUT1, and GLUT8 were found to exist in the normal heart, 14 but membrane translocation of GLUT4 was the only one to be suppressed by the increased levels of the proinflammatory cytokines. 44 In our previous study, it was demonstrated that increased expression of inflammatory factors following CPB,
In vivo deliver of AS160-4P abolished AMPK-modulated cardioprotective effect. Transfection of AS160-4P was performed 1 wk before the surgeries. The following assays were detected at preoperation and at 2 h post-CPB, and AICAR was infused 5 min before all the operations. A, Quantification of plasma creatine kinase MB. B, Quantification of plasma troponin I. C, Quantification of myocardial ATP contents. D, Representative echocardiographic images. E, Quantification of left ventricular ejection fraction (LVEF). F, Quantification of left ventricular end-systolic dimension (LVESD). Data were shown as the mean ± SEM from 3 to 6 independent experiments. *P < 0.05 vs both the groups before CPB, # P < 0.05 vs the CPB treated with empty PCAGGS group 2 h after CPB which might lead to systematic and myocardial glucose metabolic disorders. 9 Numerous studies have shown that ATP generation by glucose oxidation is the most energetically favorable way in the physiological conditions. 45 In patients with heart failure, decreased myocardial glucose uptake and utilization is one of the most important reasons leading to cardiac dysfunction. 46 In patients with diabetes, studies have also confirmed that diminished myocardial glucose uptake is a key reason for diabetic cardiomyopathy. 47 In addition, it has been confirmed that in patients with myocardial infarction, impaired myocardial glucose uptake is one of the leading causes of cardiac dysfunction. 48 Thus, post-CPB energy shortage in the myocardium might be provoked by decreased myocardial glucose uptake and utilization-that results in cardiac dysfunction.
In addition, myocardial dysfunction induced by CPB is a key reason for the complications and mortality commonly seen in patients.
Thus, it is particularly important to seek an effective method that alleviates CPB-induced acute myocardial glucose metabolism disorders in order to improve the prognosis in those patients undergoing CPB.
Our recent studies proved that intensive insulin therapy during cardiac surgery decreased myocardial injury and improved patient prognosis. 10, 49 In this study, it was illustrated that the mechanism responsible for post-CPB myocardial glucose metabolic disorders was due to the down-regulation of myocardial membrane Glut-4 distribution. It has been demonstrated that in vitro activation of AMPK restores glucose metabolism by alleviating myocardial insulin resistance. 22 A recent study also found that activation of AMPK by AICAR dampened myocardial ischemiareperfusion injury. 50 However, whether the activation of AMPK improves acute myocardial glucose metabolic disorder induced by CPB has not been previously reported in the literature.
In this study, we proved for the first time that preactivation of AMPK significantly improved myocardial glucose uptake and increased ATP supply in the early stage of CPB, which was speculated as the alleviation myocardial glucose metabolic disorders.
Meanwhile, preactivation of AMPK also significantly reduced plasma glucose level 2 hours after CPB (as shown in Figures S1-S4 ).
Additionally, we have identified that hyperglycemia was an independent risk factor for mortality in patients undergoing CPB.
51 Therefore, decreased blood glucose level by the activation of AMPK might represent an important protective mechanism to protect heart from myocardial injury. Accordingly, it was demonstrated in this study that administration of the AMPK agonist AICAR at the beginning of CPB-enhanced myocardial glucose uptake, and thus significantly alleviated cardiac injury, which led to improved cardiac function after CPB.
In conclusion, AMPK plays an important role in regulating myocardial glucose disorders in the setting of cardiac surgeries.
Preactivation of AMPK by AICAR treatment was proved to be beneficial, mediated by enhanced myocardial glucose uptake and cardiac function. Moreover, these data provided a clinical insight of the possible molecular mechanism of acute myocardial glucose metabolic disorder after CPB surgery, which highlights a potential therapeutic target for the post-CPB cardiac dysfunction.
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